共 50 条
When InO says no: understanding escape
被引:0
|作者:
Boer, Judith M.
[1
]
Zwaan, C. Michel
[1
,2
]
机构:
[1] Princess Maxima Ctr Pediat Oncol, Nijmegen, Netherlands
[2] Erasmus MC Sophia Childrens Hosp, Rotterdam, Netherlands
来源:
关键词:
ALC;
absolute lymphocyte count;
ANC;
absolute neutrophil count;
ENT;
ear;
nose;
and throat;
HPV;
human papillomavirus;
URTI;
upper respiratory tract infection;
INOTUZUMAB OZOGAMICIN;
EXPRESSION;
D O I:
10.1182/blood.2024024713
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
CD22 is expressed in almost all cases of B-cell acute lymphoblastic leukemia (B-ALL) and is therefore an attractive therapeutic target. In this issue of Blood , Zhao and colleagues identified genetic aberrations that impaired clinical response to the CD22-directed antibody-drug conjugate inotuzumab ozogamicin (InO) in adult patients with relapsed or refractory B-ALL. 1 Using extensive analysis of pre- and posttreatment patient samples, the authors identified genetic aberrations associated with primary and acquired resistance to InO.
引用
收藏
页码:2 / 4
页数:3
相关论文